Bicara Therapeutics (BCAX) Set to Announce Earnings on Monday

Bicara Therapeutics (NASDAQ:BCAX) is projected to issue its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Bicara Therapeutics to post earnings of ($0.84) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 12:30 PM ET.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.82). On average, analysts expect Bicara Therapeutics to post ($3.49) EPS for the current fiscal year and ($3.76) EPS for the next fiscal year.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $9.13 on Monday. The firm has a market cap of $604.13 million, a PE ratio of -2.95 and a beta of -0.32. The stock has a 50 day moving average of $19.74 and a 200 day moving average of $21.16. Bicara Therapeutics has a 12 month low of $8.36 and a 12 month high of $30.99.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. HSBC downgraded shares of Bicara Therapeutics to an “equal weight” rating in a research report on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a report on Thursday, September 10th. Mizuho boosted their price target on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. Finally, Benchmark reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.91.

Insiders Place Their Bets

In other Bicara Therapeutics news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the sale, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.97, for a total value of $349,625.00. Following the completion of the sale, the chief financial officer directly owned 129,855 shares in the company, valued at approximately $3,632,044.35. The trade was a 8.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,750 shares of company stock valued at $1,554,800 in the last ninety days. Insiders own 13.80% of the company’s stock.

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-?), a signaling protein that can contribute to tumor growth and immune suppression.